A carregar...

Akt shows variable sensitivity to an Hsp90 inhibitor depending on cell context

Hsp90 inhibitors are currently in clinical trials for cancer therapy based on their ability to promote proteasomal degradation of oncogenic protein kinases and nuclear receptors. Results from recent studies suggest that cancer cells are more sensitive to these inhibitors than cells from healthy tiss...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Theodoraki, Maria A., Kunjappu, Mary, Sternberg, David W., Caplan, Avrom J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2007
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2099248/
https://ncbi.nlm.nih.gov/pubmed/17643429
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.yexcr.2007.06.022
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!